Expert consensus on palivizumab use for respiratory syncytial virus in developed countries

Manuel Sánchez Luna, Paolo Manzoni, Bosco Paes, Eugenio Baraldi, Veerle Cossey, Amir Kugelman, Rupesh Chawla, Andrea Dotta, Rosa Rodríguez Fernández, Bernhard Resch, Xavier Carbonell-Estrany

Research output: Contribution to journalReview article

Abstract

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV.

Original languageEnglish
JournalPaediatric Respiratory Reviews
DOIs
Publication statusE-pub ahead of print - Dec 18 2018

Fingerprint

Respiratory Syncytial Viruses
Developed Countries
Guidelines
Respiratory Syncytial Virus Infections
Bronchopulmonary Dysplasia
Israel
Down Syndrome
Premature Infants
Cystic Fibrosis
Lung Diseases
Gestational Age
Cost-Benefit Analysis
Canada
Publications
Heart Diseases
Hospitalization
Chronic Disease
Delivery of Health Care
Lung
Population

Cite this

Luna, M. S., Manzoni, P., Paes, B., Baraldi, E., Cossey, V., Kugelman, A., ... Carbonell-Estrany, X. (2018). Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatric Respiratory Reviews. https://doi.org/10.1016/j.prrv.2018.12.001

Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. / Luna, Manuel Sánchez; Manzoni, Paolo; Paes, Bosco; Baraldi, Eugenio; Cossey, Veerle; Kugelman, Amir; Chawla, Rupesh; Dotta, Andrea; Fernández, Rosa Rodríguez; Resch, Bernhard; Carbonell-Estrany, Xavier.

In: Paediatric Respiratory Reviews, 18.12.2018.

Research output: Contribution to journalReview article

Luna, MS, Manzoni, P, Paes, B, Baraldi, E, Cossey, V, Kugelman, A, Chawla, R, Dotta, A, Fernández, RR, Resch, B & Carbonell-Estrany, X 2018, 'Expert consensus on palivizumab use for respiratory syncytial virus in developed countries', Paediatric Respiratory Reviews. https://doi.org/10.1016/j.prrv.2018.12.001
Luna, Manuel Sánchez ; Manzoni, Paolo ; Paes, Bosco ; Baraldi, Eugenio ; Cossey, Veerle ; Kugelman, Amir ; Chawla, Rupesh ; Dotta, Andrea ; Fernández, Rosa Rodríguez ; Resch, Bernhard ; Carbonell-Estrany, Xavier. / Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. In: Paediatric Respiratory Reviews. 2018.
@article{5989f908dfdd439fb14a0f0f73b30512,
title = "Expert consensus on palivizumab use for respiratory syncytial virus in developed countries",
abstract = "Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV.",
author = "Luna, {Manuel S{\'a}nchez} and Paolo Manzoni and Bosco Paes and Eugenio Baraldi and Veerle Cossey and Amir Kugelman and Rupesh Chawla and Andrea Dotta and Fern{\'a}ndez, {Rosa Rodr{\'i}guez} and Bernhard Resch and Xavier Carbonell-Estrany",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "12",
day = "18",
doi = "10.1016/j.prrv.2018.12.001",
language = "English",
journal = "Paediatric Respiratory Reviews",
issn = "1526-0542",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Expert consensus on palivizumab use for respiratory syncytial virus in developed countries

AU - Luna, Manuel Sánchez

AU - Manzoni, Paolo

AU - Paes, Bosco

AU - Baraldi, Eugenio

AU - Cossey, Veerle

AU - Kugelman, Amir

AU - Chawla, Rupesh

AU - Dotta, Andrea

AU - Fernández, Rosa Rodríguez

AU - Resch, Bernhard

AU - Carbonell-Estrany, Xavier

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/12/18

Y1 - 2018/12/18

N2 - Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV.

AB - Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV.

U2 - 10.1016/j.prrv.2018.12.001

DO - 10.1016/j.prrv.2018.12.001

M3 - Review article

C2 - 31060948

JO - Paediatric Respiratory Reviews

JF - Paediatric Respiratory Reviews

SN - 1526-0542

ER -